Menasu (Fentanyl)

Fentanyl works by binding to μ‑opioid receptors in the brain and spinal cord. This binding blocks the release of pain‑transmitting neurotransmitters, reducing neuronal excitability and the perception of pain. Its high lipophilicity enables quick entry into the central nervous system, providing fast onset of analgesia.

The specific dose of Menasu is determined by the prescribing clinician based on the patient’s pain severity, opioid tolerance, and overall clinical condition. Dosage adjustments are made individually, and patients should follow the exact instructions provided by their healthcare professional.

Fentanyl, including Menasu, is generally contraindicated during pregnancy and lactation unless the potential benefit justifies the risk. Opioids can cause fetal respiratory depression and may be excreted in breast milk. Consultation with a specialist obstetrician or neonatologist is essential before use.

To order Menasu, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Menasu delivers fentanyl via the sublingual route, offering faster onset than oral morphine or oxycodone. Its potency is roughly 50‑100 times that of morphine, allowing lower dose volumes. However, the high potency also raises the risk of respiratory depression, so careful titration and monitoring are required.

Menasu should be stored at temperatures below 25 °C, in its original packaging, protected from moisture, light, and excessive heat. Keep the product out of reach of children and unauthorized personnel. Do not refrigerate or freeze unless the manufacturer’s label specifically states otherwise.

Menasu is placed sublingually, meaning the tablet or film is positioned under the tongue and allowed to dissolve completely without chewing or swallowing. The patient should remain still for a few minutes to ensure full absorption and avoid eating or drinking until the dosage form has fully dissolved.

The most critical risks include respiratory depression, which can be fatal if not recognized promptly, severe hypotension, and chest wall rigidity that may impair breathing. Patients should be monitored closely for signs of slowed breathing, low blood pressure, or unusual muscle stiffness, especially after dose initiation or escalation.

Menasu should not be used by individuals who are opioid‑naïve, have a known hypersensitivity to fentanyl or any excipients, are taking MAO inhibitors, or have uncontrolled severe respiratory conditions. It is also contraindicated in patients with significant head injury, increased intracranial pressure, or severe hepatic impairment without specialist guidance.